Pharmacodynamics and pharmacokinetics of antibacterial drugs in the management of febrile neutropenia

The Lancet Infectious Diseases

Volumn 8, Issue 10, 2008, Pages 612-620

  Lortholary, Olivier ^a   Lefort, Agnès ^b   Tod, Michel ^c,d   Chomat, Anne Marie ^a   Darras Joly, Clémence ^e   Cordonnier, Catherine ^f  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b BEAUJON HOSPITAL   (France)

^c université Paris Cité   (France)

^d UNIVERSITÉ CLAUDE BERNARD LYON 1   (France)

^e HÔPITAL CHARLES NICOLLE   (France)

^f HENRI MONDOR HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE; AMOXICILLIN; AZLOCILLIN; CEFAZOLIN; CEFEPIME; CEFOTAXIME; CEFPIROME; CEFTAZIDIME; CEFTRIAXONE; CIPROFLOXACIN; GENTAMICIN; IMIPENEM; ISEPAMICIN; LATAMOXEF; LINEZOLID; LOMEFLOXACIN; MEROPENEM; MEZLOCILLIN; NETILMICIN; ORITAVANCIN; PIPERACILLIN; QUINOLONE DERIVATIVE; TEICOPLANIN; TICARCILLIN; TOBRAMYCIN; VANCOMYCIN;

ATTENTION; CLINICAL STUDY; CLINICAL TRIAL; CONTINUOUS INFUSION; DRUG BLOOD LEVEL; DRUG HALF LIFE; EXPERIMENTAL STUDY; FEBRILE NEUTROPENIA; HOST; HUMAN; MONITORING; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; REVIEW; SEPSIS;

EID: 52049122621     PISSN: 14733099     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1473-3099(08)70228-7     Document Type: Review

References (106)

1. Bodey G.P., Buckley M., Sathe Y.S., and Freireich E.J. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 64 (1966) 328-340
2. Dale D.C., Guerry D., Wewerka J.R., Bull J.M., and Chusid M.J. Chronic neutropenia. Medicine (Baltimore) 58 (1979) 128-144
3. Hughes W.T., Armstrong D., Bodey G.P., et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 34 (2002) 730-751
4. Cordonnier C., Buzyn A., Leverger G., et al. Epidemiology and risk factors for Gram-positive coccal infections in neutropenia: toward a more targeted antibiotic strategy. Clin Infect Dis 36 (2003) 149-158
5. Rolston K.V. Challenges in the treatment of infections caused by Gram-positive and Gram-negative bacteria in patients with cancer and neutropenia. Clin Infect Dis 40 suppl 4 (2005) S246-S252
6. Chatzinikolaou I., Abi-Said D., Bodey G.P., Rolston K.V., Tarrand J.J., and Samonis G. Recent experience with Pseudomonas aeruginosa bacteremia in patients with cancer: retrospective analysis of 245 episodes. Arch Intern Med 160 (2000) 501-509
7. Rolston K.V. New trends in patient management: risk-based therapy for febrile patients with neutropenia. Clin Infect Dis 29 (1999) 515-521
8. Klastersky J., Paesmans M., Rubenstein E.B., et al. The Multinational Association for Supportive Care in Cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 18 (2000) 3038-3051
9. Craig W.A. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 26 (1998) 1-10
10. Drusano G.L., Johnson D.E., Rosen M., and Standiford H.C. Pharmacodynamics of a fluoroquinolone antimicrobial agent in a neutropenic rat model of Pseudomonas sepsis. Antimicrob Agents Chemother 37 (1993) 483-490
11. Lortholary O., Tod M., Rizzo N., et al. Population pharmacokinetic study of teicoplanin in severely neutropenic patients. Antimicrob Agents Chemother 40 (1996) 1242-1247
12. Tod M., Lortholary O., Seytre D., et al. Population pharmacokinetic study of amikacin administered once or twice daily to febrile, severely neutropenic adults. Antimicrob Agents Chemother 42 (1998) 849-856
13. Forrest A., Nix D.E., Ballow C.H., Goss T.F., Birmingham M.C., and Schentag J.J. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother 37 (1993) 1073-1081
14. Sculier J.P., and Klastersky J. Significance of serum bactericidal activity in Gram-negative bacillary bacteremia in patients with and without granulocytopenia. Am J Med 76 (1984) 429-435
15. Craig W. Pharmacodynamics of antimicrobial agents as a basis for determining dosage regimens. Eur J Clin Microbiol Infect Dis 12 suppl 1 (1993) S6-S8
16. Leggett J.E., Fantin B., Ebert S., et al. Comparative antibiotic dose-effect relations at several dosing intervals in murine pneumonitis and thigh-infection models. J Infect Dis 159 (1989) 281-292
17. Roosendaal R., Bakker-Woudenberg I.A., van den Berghe-van Raffe M., and Michel M.F. Continuous versus intermittent administration of ceftazidime in experimental Klebsiella pneumoniae pneumonia in normal and leukopenic rats. Antimicrob Agents Chemother 30 (1986) 403-408
18. Gerber A.U., Craig W.A., Brugger H.P., Feller C., Vastola A.P., and Brandel J. Impact of dosing intervals on activity of gentamicin and ticarcillin against Pseudomonas aeruginosa in granulocytopenic mice. J Infect Dis 147 (1983) 910-917
19. Gerber A.U., Brugger H.P., Feller C., Stritzko T., and Stalder B. Antibiotic therapy of infections due to Pseudomonas aeruginosa in normal and granulocytopenic mice: comparison of murine and human pharmacokinetics. J Infect Dis 153 (1986) 90-97
20. Shapiro M.A., Dever J.A., Sesnie J.C., and VanderRoest S.R. Comparative therapeutic efficacy of clinafloxacin in leucopenic mice. J Antimicrob Chemother 39 (1997) 273-276
21. Levison M.E. Pharmacodynamics of antimicrobial drugs. Infect Dis Clin North Am 18 (2004) 451-465
22. Navas D., Caillon J., Batard E., et al. Trough serum concentrations of beta-lactam antibiotics in cancer patients: inappropriateness of conventional schedules to pharmacokinetic/pharmacodynamic properties of beta-lactams. Int J Antimicrob Agents 27 (2006) 102-107
23. Nyhlen A., Ljungberg B., and Nilsson-Ehle I. Pharmacokinetics of ceftazidime in febrile neutropenic patients. Scand J Infect Dis 33 (2001) 222-226
24. Pea F., Viale P., Damiani D., et al. Ceftazidime in acute myeloid leukemia patients with febrile neutropenia: helpfulness of continuous intravenous infusion in maximizing pharmacodynamic exposure. Antimicrob Agents Chemother 49 (2005) 3550-3553
25. Daenen S., Erjavec Z., Uges D.R., De Vries-Hospers H.G., De Jonge P., and Halie M.R. Continuous infusion of ceftazidime in febrile neutropenic patients with acute myeloid leukemia. Eur J Clin Microbiol Infect Dis 14 (1995) 188-192
26. Egerer G., Goldschmidt H., Hensel M., et al. Continuous infusion of ceftazidime for patients with breast cancer and multiple myeloma receiving high-dose chemotherapy and peripheral blood stem cell transplantation. Bone Marrow Transplant 30 (2002) 427-431
27. Dalle J.H., Gnansounou M., Husson M.O., Lambilliotte A., Mazingue F., and Nelken B. Continuous infusion of ceftazidime in the empiric treatment of febrile neutropenic children with cancer. J Pediatr Hematol Oncol 24 (2002) 714-716
28. Tod M, Denelle S, Lortholary O, et al. Pharmacokinetic-pharmacodynamic study of cefpirome administered by continuous infusion to febrile neutropenic adults. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy; San Diego, CA, USA; Sept 27-30, 2002. Abstract A-1401.
29. Nyhlen A., Ljungberg B., and Nilsson-Ehle I. Pharmacokinetics of meropenem in febrile neutropenic patients. Swedish study group. Eur J Clin Microbiol Infect Dis 16 (1997) 797-802
30. Drusano G.L., Plaisance K.I., Forrest A., et al. Steady-state pharmacokinetics of imipenem in febrile neutropenic cancer patients. Antimicrob Agents Chemother 31 (1987) 1420-1422
31. Drusano G.L., Standiford H.C., Bustamante C., et al. Multiple-dose pharmacokinetics of imipenem-cilastatin. Antimicrob Agents Chemother 26 (1984) 715-721
32. Drusano G.L., de Jongh C., Newman K., et al. Moxalactam and piperacillin: a study of in vitro characteristics and pharmacokinetics in cancer patients. Infection 13 (1985) 20-26
33. Drusano G.L., Forrest A., Plaisance K.I., and Wade J.C. A prospective evaluation of optimal sampling theory in the determination of the steady-state pharmacokinetics of piperacillin in febrile neutropenic cancer patients. Clin Pharmacol Ther 45 (1989) 635-641
34. Lau A., Lee M., and Sharifi R. Pharmacokinetics of piperacillin in hospitalized patients. Int J Clin Pharmacol Ther Toxicol 23 (1985) 391-394
35. Standiford H.C., Drusano G.L., McNamee W.B., Tatem B., Ryan P.A., and Schimpff S.C. Comparative pharmacokinetics of moxalactam, cefoperazone, and cefotaxime in normal volunteers. Rev Infect Dis 4 suppl (1982) S585-S594
36. Ariano R.E., Nyhlen A., Donnelly J.P., Sitar D.S., Harding G.K., and Zelenitsky S.A. Pharmacokinetics and pharmacodynamics of meropenem in febrile neutropenic patients with bacteremia. Ann Pharmacother 39 (2005) 32-38
37. Craig W.A., and Ebert S.C. Continuous infusion of beta-lactam antibiotics. Antimicrob Agents Chemother 36 (1992) 2577-2583
38. Lortholary O., Tod M., Cohen Y., and Petitjean O. Aminoglycosides. Med Clin North Am 79 (1995) 761-787
39. Paul M., Soares-Weiser K., Grozinsky S., and Leibovici L. Beta-lactam versus beta-lactam-aminoglycoside combination therapy in cancer patients with neutropaenia. Cochrane Database Syst Rev 3 (2003) CD003038.
40. Furno P., Bucaneve G., and Del Favero A. Monotherapy or aminoglycoside-containing combinations for empirical antibiotic treatment of febrile neutropenic patients: a meta-analysis. Lancet Infect Dis 2 (2002) 231-242
41. De Pauw B.E., Deresinski S.C., Feld R., Lane-Allman E.F., and Donnelly J.P. Ceftazidime compared with piperacillin and tobramycin for the empiric treatment of fever in neutropenic patients with cancer. A multicenter randomized trial. Ann Intern Med 120 (1994) 834-844
42. Cometta A., Calandra T., Gaya H., et al. Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. Antimicrob Agents Chemother 40 (1996) 1108-1115
43. Del Favero A., Menichetti F., Martino P., et al. A multicenter, double-blind, placebo-controlled trial comparing piperacillin-tazobactam with and without amikacin as empiric therapy for febrile neutropenia. Clin Infect Dis 33 (2001) 1295-1301
44. Drgona L., Paul M., Bucaneve G., Calandra T., and Menichetti F. The need for aminoglycosides in combination with b-lactams for high-risk, febrile neutropaenic patients with leukaemia. EJC Supplements (2007) 13-22
45. Gilbert D.N. Aminoglycosides. In: Mandell G.L., Bennett J.E., and Dolin R. (Eds). Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases, 6th edn (2005), Elsevier Churchill Livingstone, Pennsylvania, USA 328-356
46. Fantin B., Ebert S., Leggett J., Vogelman B., and Craig W.A. Factors affecting duration of in-vivo postantibiotic effect for aminoglycosides against Gram-negative bacilli. J Antimicrob Chemother 27 (1991) 829-836
47. Minguez F.M., Izquierdo J.I., Caminero M.M., Martinez F.F., and Prieto Prieto J. In vivo postantibiotic effect of isepamicin and other aminoglycosides in a thigh infection model in neutropenic mice. Chemotherapy 38 (1992) 179-184
48. Gerber A.U., Kozak S., Segessenmann C., Fluckiger U., Bangerter T., and Greter U. Once-daily versus thrice-daily administration of netilmicin in combination therapy of Pseudomonas aeruginosa infection in a man-adapted neutropenic animal model. Eur J Clin Microbiol Infect Dis 8 (1989) 233-237
49. Kapusnik J.E., Hackbarth C.J., Chambers H.F., Carpenter T., and Sande M.A. Single, large, daily dosing versus intermittent dosing of tobramycin for treating experimental pseudomonas pneumonia. J Infect Dis 158 (1988) 7-12
50. Darras-Joly C., Bedos J.P., Sauve C., et al. Synergy between amoxicillin and gentamicin in combination against a highly penicillin-resistant and tolerant strain of Streptococcus pneumoniae in a mouse pneumonia model. Antimicrob Agents Chemother 40 (1996) 2147-2151
51. Onyeji C.O., Nicolau D.P., Nightingale C.H., and Bow L. Modulation of efficacies and pharmacokinetics of antibiotics by granulocyte colony-stimulating factor in neutropenic mice with multidrug-resistant Enterococcus faecalis infection. J Antimicrob Chemother 46 (2000) 429-436
52. Kaojarern S., Maoleekoonpairoj S., and Atichartakarn V. Pharmacokinetics of amikacin in hematologic malignancies. Antimicrob Agents Chemother 33 (1989) 1406-1408
53. Davis R.L., Lehmann D., Stidley C.A., and Neidhart J. Amikacin pharmacokinetics in patients receiving high-dose cancer chemotherapy. Antimicrob Agents Chemother 35 (1991) 944-947
54. Phillips J.K., Spearing R.L., Crome D.J., and Davies J.M. Gentamicin volumes of distribution in patients with hematologic disorders. N Engl J Med 319 (1988) 1290
55. Bianco T.M., Dwyer P.N., and Bertino J.S. Gentamicin pharmacokinetics, nephrotoxicity, and prediction of mortality in febrile neutropenic patients. Antimicrob Agents Chemother 33 (1989) 1890-1895
56. Higa G.M., and Murray W.E. Alterations in aminoglycoside pharmacokinetics in patients with cancer. Clin Pharm 6 (1987) 963-966
57. Zeitany R.G., el Saghir N.S., Santhosh-Kumar C.R., and Sigmon M.A. Increased aminoglycoside dosage requirements in hematologic malignancy. Antimicrob Agents Chemother 34 (1990) 702-708
58. Hary L., Andrejak M., Bernaert F., and Desablens B. Pharmacokinetics of amikacin in neutropenic patients. Curr Ther Res 46 (1989) 821-827
59. Bertino J.S., Booker L.A., Franck P., and Rybicki B. Gentamicin pharmacokinetics in patients with malignancies. Antimicrob Agents Chemother 35 (1991) 1501-1503
60. Finley R.S., Fortner C.L., deJongh C.A., et al. Comparison of standard versus pharmacokinetically adjusted amikacin dosing in granulocytopenic cancer patients. Antimicrob Agents Chemother 22 (1982) 193-197
61. Romano S., de Gatta M.F., Calvo M.V., Caballero D., Dominguez-Gil A., and Lanao J.M. Population pharmacokinetics of amikacin in patients with haematological malignancies. J Antimicrob Chemother 44 (1999) 235-242
62. Krivoy N., Postovsky S., Elhasid R., and Ben Arush M.W. Pharmacokinetic analysis of amikacin twice and single daily dosage in immunocompromised pediatric patients. Infection 26 (1998) 396-398
63. Peterson A.K., and Duffull S.B. Population analysis of once-daily dosing of gentamicin in patients with neutropenia. Aust N Z J Med 28 (1998) 311-315
64. Manny R.P., and Hutson P.R. Aminoglycoside volume of distribution in hematology-oncology patients. Clin Pharm 5 (1986) 629 632.
65. Dupuis L.L., Sung L., Taylor T., et al. Tobramycin pharmacokinetics in children with febrile neutropenia undergoing stem cell transplantation: once-daily versus thrice-daily administration. Pharmacotherapy 24 (2004) 564-573
66. Tod M., Padoin C., and Petitjean O. Clinical pharmacokinetics and pharmacodynamics of isepamicin. Clin Pharmacokinet 38 (2000) 205-223
67. Meunier F., Van der Auwera P., Aoun M., Ibrahim S., and Tulkens P.M. Empirical antimicrobial therapy with a single daily dose of ceftriaxone plus amikacin in febrile granulocytopenic patients: a pilot study. J Antimicrob Chemother 27 suppl C (1991) 129-139
68. Viscoli C., Dudley M., Ferrea G., et al. Serum concentrations and safety of single daily dosing of amikacin in children undergoing bone marrow transplantation. J Antimicrob Chemother 27 suppl C (1991) 113-120
69. Anon. Efficacy and toxicity of single daily doses of amikacin and ceftriaxone versus multiple daily doses of amikacin and ceftazidime for infection in patients with cancer and granulocytopenia. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. Ann Intern Med 119 (1993) 584-593
70. Cometta A., Zinner S., de Bock R., et al. Piperacillin-tazobactam plus amikacin versus ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. Antimicrob Agents Chemother 39 (1995) 445-452
71. Rozdzinski E., Kern W.V., Reichle A., et al. Once-daily versus thrice-daily dosing of netilmicin in combination with beta-lactam antibiotics as empirical therapy for febrile neutropenic patients. J Antimicrob Chemother 31 (1993) 585-598
72. Sanz M.A., Lopez J., Lahuerta J.J., et al. Cefepime plus amikacin versus piperacillin-tazobactam plus amikacin for initial antibiotic therapy in haematology patients with febrile neutropenia: results of an open, randomized, multicentre trial. J Antimicrob Chemother 50 (2002) 79-88
73. Cornely O.A., Bethe U., Salzberger B., et al. Randomized controlled monocentric comparison of once daily ceftriaxone with tobramycin and cefotaxime three times daily with tobramycin in neutropenic fever. Ann Hematol 80 (2001) 103-108
74. Bakri F.E., Pallett A., Smith A.G., and Duncombe A.S. Once-daily versus multiple-daily gentamicin in empirical antibiotic therapy of febrile neutropenia following intensive chemotherapy. J Antimicrob Chemother 45 (2000) 383-386
75. Rodman D.P., Maxwell A.J., and McKnight J.T. Extended dosage intervals for aminoglycosides. Am J Hosp Pharm 51 (1994) 2016-2021
76. Sung L., Dupuis L.L., Bliss B., et al. Randomized controlled trial of once versus thrice-daily tobramycin in febrile neutropenic children undergoing stem cell transplantation. J Natl Cancer Inst 95 (2003) 1869-1877
77. Torfoss D., Hoiby E.A., Tangen J.M., et al. Tobramycin once versus three times daily, given with penicillin G, to febrile neutropenic cancer patients in Norway: a prospective, randomized, multicentre trial. J Antimicrob Chemother 59 (2007) 711-717
78. Hatala R., Dinh T.T., and Cook D.J. Single daily dosing of aminoglycosides in immunocompromised adults: a systematic review. Clin Infect Dis 24 (1997) 810-815
79. Torney H.L., Balistreri F.J., Kenny M.T., and Cheng W.D. Comparative therapeutic efficacy of teicoplanin and vancomycin in normal and in neutropenic mice infected with Staphylococcus haemolyticus. J Antimicrob Chemother 28 (1991) 261-269
80. Candiani G., Abbondi M., Borgonovi M., and Williams R. Experimental lobar pneumonia due to penicillin-susceptible and penicillin-resistant Streptococcus pneumoniae in immunocompetent and neutropenic rats: efficacy of penicillin and teicoplanin treatment. J Antimicrob Chemother 39 (1997) 199-207
81. Lefort A., Saleh-Mghir A., Garry L., Carbon C., and Fantin B. Activity of LY333328 combined with gentamicin in vitro and in rabbit experimental endocarditis due to vancomycin-susceptible or -resistant Enterococcus faecalis. Antimicrob Agents Chemother 44 (2000) 3017-3021
82. Boylan C.J., Campanale K., Iversen P.W., Phillips D.L., Zeckel M.L., and Parr T.R. Pharmacodynamics of oritavancin (LY333328) in a neutropenic-mouse thigh model of Staphylococcus aureus infection. Antimicrob Agents Chemother 47 (2003) 1700-1706
83. Hyatt J.M., McKinnon P.S., Zimmer G.S., and Schentag J.J. The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome. Focus on antibacterial agents. Clin Pharmacokinet 28 (1995) 143-160
84. Moise-Broder P.A., Forrest A., Birmingham M.C., and Schentag J.J. Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections. Clin Pharmacokinet 43 (2004) 925-942
85. Zimmermann A.E., Katona B.G., and Plaisance K.I. Association of vancomycin serum concentrations with outcomes in patients with Gram-positive bacteremia. Pharmacotherapy 15 (1995) 85-91
86. de Gatta M.F., Fruns I., Hernandez J.M., et al. Vancomycin pharmacokinetics and dosage requirements in hematologic malignancies. Clin Pharm 12 (1993) 515-520
87. Le Normand Y., Milpied N., Kergueris M.F., and Harousseau J.L. Pharmacokinetic parameters of vancomycin for therapeutic regimens in neutropenic adult patients. Int J Biomed Comput 36 (1994) 121-125
88. Chang D., Liem L., and Malogolowkin M. A prospective study of vancomycin pharmacokinetics and dosage requirements in pediatric cancer patients. Pediatr Infect Dis J 13 (1994) 969-974
89. Chang D. Influence of malignancy on the pharmacokinetics of vancomycin in infants and children. Pediatr Infect Dis J 14 (1995) 667-673
90. Pea F., Viale P., Candoni A., et al. Teicoplanin in patients with acute leukaemia and febrile neutropenia: a special population benefiting from higher dosages. Clin Pharmacokinet 43 (2004) 405-415
91. Kureishi A., Jewesson P.J., Bartlett K.H., Cole C.D., and Chow A.W. Application of a modified bioassay for monitoring serum teicoplanin and vancomycin in febrile neutropenic patients. Antimicrob Agents Chemother 34 (1990) 1642-1647
92. Matzke G.R., McGory R.W., Halstenson C.E., and Keane W.F. Pharmacokinetics of vancomycin in patients with various degrees of renal function. Antimicrob Agents Chemother 25 (1984) 433-437
93. Rotschafer J.C., Crossley K., Zaske D.E., Mead K., Sawchuk R.J., and Solem L.D. Pharmacokinetics of vancomycin: observations in 28 patients and dosage recommendations. Antimicrob Agents Chemother 22 (1982) 391-394
94. Lode H., Boeckh M., Hoffken G., et al. Comparative pharmacokinetics of glycopeptide antibiotics, and the influence of teicoplanin on granulocyte function. Scand J Infect Dis Suppl 72 (1990) 9-13
95. Carver P.L., Nightingale C.H., Quintiliani R., Sweeney K., Stevens R.C., and Maderazo E. Pharmacokinetics of single and multiple-dose teicoplanin in healthy volunteers. Antimicrob Agents Chemother 33 (1989) 82-86
96. Brunet F., Vedel G., Dreyfus F., et al. Failure of teicoplanin therapy in two neutropenic patients with staphylococcal septicemia who recovered after administration of vancomycin. Eur J Clin Microbiol Infect Dis 9 (1990) 145-147
97. Wysocki M., Delatour F., Faurisson F., et al. Continuous versus intermittent infusion of vancomycin in severe staphylococcal infections: prospective multicenter randomized study. Antimicrob Agents Chemother 45 (2001) 2460-2467
98. Cullen M., Steven N., Billingham L., et al. Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas. N Engl J Med 353 (2005) 988-998
99. Bucaneve G., Micozzi A., Menichetti F., et al. Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. N Engl J Med 353 (2005) 977-987
100. Fantin B., Leggett J., Ebert S., and Craig W.A. Correlation between in vitro and in vivo activity of antimicrobial agents against Gram-negative bacilli in a murine infection model. Antimicrob Agents Chemother 35 (1991) 1413-1422
101. Leggett J.E., Ebert S., Fantin B., and Craig W.A. Comparative dose-effect relations at several dosing intervals for beta-lactam, aminoglycoside and quinolone antibiotics against Gram-negative bacilli in murine thigh-infection and pneumonitis models. Scand J Infect Dis Suppl 74 (1990) 179-184
102. Roosendaal R., Bakker-Woudenberg I.A., van den Berghe-van Raffe M., Vink-van den Berg J.C., and Michel M.F. Comparative activities of ciprofloxacin and ceftazidime against Klebsiella pneumoniae in vitro and in experimental pneumonia in leukopenic rats. Antimicrob Agents Chemother 31 (1987) 1809-1815
103. Smith G.M., Leyland M.J., Farrell I.D., and Geddes A.M. Preliminary evaluation of ciprofloxacin, a new 4-quinolone antibiotic, in the treatment of febrile neutropenic patients. J Antimicrob Chemother 18 suppl D (1986) 165-174
104. Smith G.M., Leyland M.J., Farrell I.D., and Geddes A.M. A clinical, microbiological and pharmacokinetic study of ciprofloxacin plus vancomycin as initial therapy of febrile episodes in neutropenic patients. J Antimicrob Chemother 21 (1988) 647-655
105. Birmingham M.C., Rayner C.R., Meagher A.K., Flavin S.M., Batts D.H., and Schentag J.J. Linezolid for the treatment of multidrug-resistant, Gram-positive infections: experience from a compassionate-use program. Clin Infect Dis 36 (2003) 159-168
106. Smith P.F., Birmingham M.C., Noskin G.A., et al. Safety, efficacy and pharmacokinetics of linezolid for treatment of resistant Gram-positive infections in cancer patients with neutropenia. Ann Oncol 14 (2003) 795-801